Know Cancer

or
forgot password

ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.


Phase 2
18 Years
N/A
Not Enrolling
Both
Carcinoma, Non-Small-Cell Lung

Thank you

Trial Information

ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.


Inclusion Criteria:



- You have a diagnosis of non-small cell lung cancer.

- You have received no prior chemotherapy.

- You have at least one measurable lesion.

- You have an adequate performance status.

- You are at least 18 years of age.

Exclusion Criteria:

- You have previously received chemotherapy for your lung cancer.

- You have received radiation within the last 30 days.

- You have active infection or other serious condition.

- You have brain metastasis.

- You have recently lost a significant amount of weight.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Authority:

United States: Food and Drug Administration

Study ID:

6142

NCT ID:

NCT00051493

Start Date:

April 2002

Completion Date:

December 2002

Related Keywords:

  • Carcinoma, Non-Small-Cell Lung
  • Non-Small Cell Lung Cancer
  • Lung Cancer
  • NSCLC
  • Advanced Non-Small Cell Lung Cancer
  • Carcinoma
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location

Austin, Texas  78705